Merus Labs International (TSE:MSL) Upgraded to “Moderate Buy” at Canaccord Genuity Group

Merus Labs International (TSE:MSL) (NASDAQ:MSLI) was upgraded by stock analysts at Canaccord Genuity Group to a “moderate buy” rating in a research report issued on Thursday,Zacks.com reports.

Several other brokerages also recently commented on MSL. Leerink Partners raised shares of Merus Labs International to a “strong-buy” rating in a research note on Monday, April 6th. Cantor Fitzgerald raised shares of Merus Labs International to a “strong-buy” rating in a research note on Wednesday, March 11th. Finally, Guggenheim raised shares of Merus Labs International to a “strong-buy” rating in a research note on Tuesday, April 28th. Three investment analysts have rated the stock with a Strong Buy rating and one has issued a Buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Strong Buy”.

Merus Labs International Stock Performance

Merus Labs International has a one year low of C$0.95 and a one year high of C$1.76.

About Merus Labs International

Merus Labs International Inc is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company’s products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin. Elantan are tablets or capsules that belong to a group of medicines called organic nitrates. Isoket belongs to a group of medicines called organic nitrates. Deponit belongs to a group of medicines called nitrates.